

## Appendix 2: Additional model results

### A. Vaccine price investigation

Table 1. Incremental cost per QALY gained for changing vaccine price.\*

Vaccine price (£)	Cost/QALY gained (£)
20	1,667
30	7,890
45	14,472
54	19,953
71	29,837
100	44,694

Discount rate is 3.5% for both future costs and health outcomes. \*Vaccine price is per dose, for a single dose vaccine. QALY: quality-adjusted life year

### B. Scenario analysis results

Table 2. Alternative scenarios explored, their cost-effectiveness and their maximum cost-effective vaccine price.

Scenario	Cost/QALY gained for base case (£)*	Maximum vaccine price for £20k/ QALY threshold (£)
Vaccine prevents 1% of stillbirths	9,511	94
Vaccine prevents 1% of preterm births	16,892	59
Vaccine prevents 1% of stillbirths and 1% of preterm births	8,052	100
1% of maternal disease cases result in a fatality	19,745	54
Inclusion of quality of life effect of GBS disease on carers (QALYs lost by infants multiplied with health spillover multiplier and divided by displaced QALY multiplier)	17,735	60
'Most favourable': Vaccine prevents 1% of stillbirths and 1% of preterm births; 1% of maternal disease cases result in a fatality; carer QALYs included	7,775	107
Trivalent vaccine	25,543	46
£15k cost/ QALY threshold and 1.5% discount rate	8,191	78**

Discount rate is 3.5% for both future costs and health outcomes. \*vaccine price = £54/dose, \*\*£15k threshold applied here. QALY: quality-adjusted life year, GBS: group B *Streptococcus*